Observational Study in Type 2 Diabetics Treated by an Intensive Insulin Treatment of Levemir® (LITHULEV1)

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: insulin detemir

Study type: Observational

Funder types: Industry

Identifiers

NCT00806897

NN304-3701

Details and patient eligibility

About

This study is conducted in Europe. The aim of this observational study is to gain practical experience with once daily Levemir® administration in type 2 diabetes patients who were previously treated with NPH insulins (e.g. Protaphane®) as basal insulin as part of their IIT under normal clinical practice conditions in Lithuania

Enrollment: 74 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 diabetic subjects on intensive insulin treatment (IIT)
• Eligibility for once daily insulin detemir administration
• Informed consent obtained before any observation-related activities

Exclusion criteria

• Known or suspected allergy to insulin detemir
• Subjects previously enrolled in the observation
• Women who are pregnant, breast feeding or have the intention of becoming pregnant within 6 months

Trial design

74 participants in 1 patient group

A

Treatment:

Drug: insulin detemir